Oisin Biotechnologies could be on the verge of cancer and antiaging breakthroughs

by

Clearing old “zombie” cells from the human body has been shown to extend the lives of mice.

When cells detect that they have been irreversibly damaged, they enter a non-dividing condition known as cell-cycle arrest, or senescence. It’s believed this occurs to prevent cells from going rogue and turning cancerous. Ideally, they should die by the process known as apoptosis, but as we age, more and more frequently they don’t. They become zombie cells – unable to kill themselves or resume normal function.

Senescent cells secrete molecules that cause inflammation in an effort to attract immune cells that would usually clear them. But for reasons that are not fully known, as we age, persistently senescent cells accumulate, leading to a vast number of age-related diseases.

Oisín is developing a highly precise, patent-pending, DNA-targeted intervention to clear these cells.

Oisin Biotechnologies will start clinical trials testing senescent cell human trials should start in 2019 with the target of fighting cancer. These clinical trials will be to use repeated dosing of lipids with gene therapy to trigger cell death in cells that show P19 and other active genes.

Oisin has been able to repeatedly and safely apply gene therapy safely throughout the bodies of mice and monkeys.

Repeated dosing has been shown to reduce tumor size and control certain cancers in mouse models. They have tested repeated dosing in monkeys as well.

The phase 1 and phase 2 clinical trials will hopefully prove that the repeated dosing is safe and effective in humans.

In Canada, Oisin will be able to take cancer patients with any type of cancer. Oisin will proceed to later phases against the cancers which respond best to their treatments.

Repeated dosing to achieve antiaging breakthrough 5-year old mice

In the antiaging trials on mice, 90% 2-year-old mice that received one dose of the combination treatment survived to 2.5 years while only 50% of untreated mice survived.

If repeated dosing was as effective as the first 6 months then 53% of the mice might survive to 5 years of age. (0.9*0.9*0.9*0.9*0.9*0.9 = 0.53). This would mean the Antiaging Mouse prize would be won. The optimal dosing schedule to keep senescent cells cleared might be even more frequent than once every 6 months in mice. It might be once every month or two.

Aubrey de Grey and SENS have talked about robust mouse rejuvenation being the key milestone for antiaging. By 2021, we could know if Oisin Biotech can achieve it with repeated dosing of senescent cell clearing.

19 thoughts on “Oisin Biotechnologies could be on the verge of cancer and antiaging breakthroughs”

  1. I landed here researching the main themes at RAADfest and I am not sure if these comments are from people genuinely interested in an area which is exploding or they are taking part in a secret contest of who can be the rudest to the author? Mainly I was looking to see if there is any data past the 140 week mark to see how p53 plus p16 is doing now ? Thanks

  2. I landed here researching the main themes at RAADfest and I am not sure if these comments are from people genuinely interested in an area which is exploding or they are taking part in a secret contest of who can be the rudest to the author?Mainly I was looking to see if there is any data past the 140 week mark to see how p53 plus p16 is doing now ?Thanks

  3. I landed here researching the main themes at RAADfest and I am not sure if these comments are from people genuinely interested in an area which is exploding or they are taking part in a secret contest of who can be the rudest to the author? Mainly I was looking to see if there is any data past the 140 week mark to see how p53 plus p16 is doing now ? Thanks

  4. I landed here researching the main themes at RAADfest and I am not sure if these comments are from people genuinely interested in an area which is exploding or they are taking part in a secret contest of who can be the rudest to the author?Mainly I was looking to see if there is any data past the 140 week mark to see how p53 plus p16 is doing now ?Thanks

  5. I landed here researching the main themes at RAADfest and I am not sure if these comments are from people genuinely interested in an area which is exploding or they are taking part in a secret contest of who can be the rudest to the author?
    Mainly I was looking to see if there is any data past the 140 week mark to see how p53 plus p16 is doing now ?

    Thanks

  8. ” Frankly, so are all academic scientists (i.e., seeking grants). I don’t expect anyone considers routine reporting of experimental results by such academic scientists to automatically be considered suspect, as you seem to suggest is the case for a commercial entity. ”

    …and that is the problem. This pedestalization of scientists people do…as if because they are not in the commercial sphere they are somehow above reproach.

    I don’t call ’em ‘grant wh0res’ for nuttin.

  9. Any chance of sticking the DRACO (double-stranded RNA activated caspase oligomerizer) inside your nanoparticles to create a broad spectrum anti viral?

  10. I assume the below paragraph is the author’s conjecture and not claimed by Osin?

    “If repeated dosing was as effective as the first 6 months then 53% of the mice might survive to 5 years of age. (0.9*0.9*0.9*0.9*0.9*0.9 = 0.53). This would mean the Antiaging Mouse prize would be won. The optimal dosing schedule to keep senescent cells cleared might be even more frequent than once every 6 months in mice. It might be once every month or two.”

  11. The cancer trial is the most straightforward path to the clinic and early approval. But your insight that there might be anti-aging benefits is a good one. Separately we are exploring more aging-indication-focused (none cancer) trials in humans, but can’t commit to a date for those as yet. Also, mouse and primate experiments are still very necessary to set the stage for a variety of human trials over the next decade.

  12. Only accredited investors can be accepted. We don’t want to run afoul of advertising or promotion rules in comments so we won’t say anything more here on this subject.

  15. Gary, thanks for your excellent reply. As far as Osin being in the process of raising $ I know it’s routine and in no way is that disqualifying, but it is somewhat of a factor to consider in contrast to say a tenured academic who has his long-term funding secure. But we really do need the private sector to lead the way in this, so all the more power to Osin. I hope they are successful in getting the word out so they can get things done expeditiously. Time is of the essence for some so I wish there could be somehow “concurrent replications” of the results, lol.

    Anyway, it says here that they’re going to have human trials next year, so you’d think that would take precedence over the mice work. It’s billed as “for cancer” so you wonder how much light that would shed on the anti-aging effect. Can’t there also be an anti-aging trial on humans next year? Certainly there’d be tons of volunteers.

  16. First, all biotech companies are always raising money, either publicly, privately or via business deals such as licensing. Frankly, so are all academic scientists (i.e., seeking grants). I don’t expect anyone considers routine reporting of experimental results by such academic scientists to automatically be considered suspect, as you seem to suggest is the case for a commercial entity.

    Second, your “sense” is correct, since the graph is labeled as “preliminary data – study on-going.” The study will continue until all animals are dead.

    Third, as with any lifespan study, it will take some time to replicate; typically one to three years.

    Separately, the reporting in the original post contains several errors. There were multiple treatments (indicated by the vertical black arrow) on one month centers, not a single treatment for the lifespan study. And the promoter that was targeted wasn’t p19, but p16, p53 or a combination of the two. Lastly, control survival was ~40% not 50%.

  17. I am very excited about this, and I don’t know everything about it, but I’ll provide a couple of devils advocate style words of caution, and if somebody could dispel my concerns, great!

    First, I ask, is Osin in the process of needing to raise a lot of money? If so, is there any question that the results they are reporting are 100% on the level? Regardless, I do get a sense that they are reporting data from a study that is still ongoing (incomplete). We still don’t know how long on average the treated mice will live. Plus, if this study is so groundbreaking then I would hope that others would make an effort to replicate it, and if we get some replications we could of course have much greater confidence in it.

Comments are closed.